Roche acquires CAPP Medical

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROCHE acquired CAPP Medical, a genomics research company founded by members of Stanford University, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.

CAPP Medical’s novel technology is designed to isolate and quantify small amounts of ctDNA through a blood draw, which can be used for cancer therapy selection and monitoring tumor response and resistance to therapy.

“Roche believes focused and high quality next generation sequencing assays using simple blood draws have the potential to significantly advance the time of cancer diagnosis and change routine cancer diagnostic monitoring and may be highly cost effective compared to today’s current standard of using PET and CT imaging to monitor tumor progression,” said Roland Diggelmann, COO of Roche Diagnostics.

CAPP Medical is a privately held company founded in October 2013. CAPP Medical’s technology focuses on assay design and the bioinformatics that allow for the detection of multiple mutations with a single assay.

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login